Today: 23 May 2026
Visa stock hit again by Trump’s 10% credit-card rate cap push as traders eye Jan. 20
14 January 2026
2 mins read

Visa stock hit again by Trump’s 10% credit-card rate cap push as traders eye Jan. 20

New York, January 14, 2026, 05:25 ET — Premarket

  • Visa shares tumbled in the last session as investors adjusted for rising political risks impacting the card ecosystem.
  • Banks and analysts cautioned that a rate cap might restrict credit availability, despite payment networks not generating interest income.
  • Traders await further details from Washington ahead of the proposed January 20 start date.

Visa Inc shares dropped 4.5%, ending Tuesday at $327.88. The move was notable for a Dow component, following renewed White House pressure on credit-card fees that rattled payments stocks.

The selloff boils down to one key factor: President Donald Trump proposed a one-year cap of 10% on credit-card interest rates starting Jan. 20, effectively setting a legal maximum on what issuers can charge. JPMorgan’s Chief Financial Officer Jeremy Barnum slammed the plan as “very bad for consumers,” warning the bank would have to scale back credit availability. Trump also backed reducing card “swipe fees” — the fees merchants pay to process transactions. Reuters

Visa cares because the policy affects its business upstream. On Monday, Visa and Mastercard dropped 1.8%, even though the rate cap would hit lenders’ interest income directly. Card-heavy lenders like Capital One, Bread Financial, and Synchrony slid between 8% and 11%, Reuters reported. UBS Global analysts said putting rate caps in place would require “an Act of Congress.” J.P. Morgan’s Vivek Juneja warned such a cap might push borrowers toward “more expensive debt” outside banks. Reuters

Tuesday saw the sell-off accelerate. Visa tumbled 4.5%, Mastercard slid 3.8%, and the financial sector dropped 1.8% as U.S. stocks closed lower, despite December’s consumer inflation hitting the expected 2.7% year-on-year, according to Reuters. “Financials are getting hit by Trump’s credit-card proposal,” said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder. Reuters

Credit cards remain among the priciest borrowing options, thanks to balances that can carry over month after month — what’s called “revolving credit.” Interest stacks up quickly if borrowers stick to minimum payments. Bankrate put the average credit card rate at 19.65%. Meanwhile, U.S. credit card debt hit $1.23 trillion by the end of Q3, Reuters reported. Jefferies analysts cautioned that tighter credit conditions might drag on retail sales and slow growth. Reuters

Visa doesn’t lend directly to consumers or earn interest on card balances. Its revenue comes from fees linked to payment volume, so the concern is indirect: if issuers reduce credit limits or shut accounts, spending could drop and transaction counts might decline.

The political angle complicates things further. The proposal came with scant details, leaving traders to guess how much is posturing versus actual legislation, and whether the scope will expand beyond interest rates to include merchant fees.

Investors are also watching a downside risk closely. Should the cap gain momentum on Capitol Hill, banks might swiftly tighten lending standards, hitting subprime borrowers hardest. That squeeze could weigh on card volumes, even if the networks avoid a direct hit to interest income.

Visa holders are keeping a close eye on Washington for clear signs—draft bills, industry talks, or any timeline updates. The next key date: Jan. 20, when Trump announced the rate cap would take effect.

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
UOB stock price today: U11 edges higher as investors line up for Feb earnings
Previous Story

UOB stock price today: U11 edges higher as investors line up for Feb earnings

Australia stock market today: ASX 200 ends at two-month high as oil and copper lift miners, banks slide
Next Story

Australia stock market today: ASX 200 ends at two-month high as oil and copper lift miners, banks slide

Go toTop